A review of low-dose ritonavir in protease inhibitor combination therapy

Clinical Infectious Diseases

Volumn 36, Issue 12, 2003, Pages 1585-1592

  Cooper, Curtis L ^a   Van Heeswijk, R P G ^a   Gallicano, K ^b   Cameron, D W ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Axelson Biopharma Research Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CYTOCHROME P450 3A4; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; CYP3A PROTEIN, HUMAN; CYTOCHROME P450;

ABDOMINAL PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEMATURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; TASTE DISORDER; TREATMENT OUTCOME; UROLITHIASIS; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; METABOLISM;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; RITONAVIR; SAQUINAVIR;

EID: 0037871892     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375233     Document Type: Review

References (88)

1. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-6.
2. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
3. Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Expert Opinion on Investigational Drugs 1998; 7:413-26.
4. Buss N. Saquinavir soft gel capsules (Fortovase): pharmacokinetics and drug interactions [abstract 354]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1998: 145.
5. Kurowski M, Kaeser B, Sawyer A, Popescu M, Mrozikiewicz A. Lowdose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther 2002; 72:123-32.
6. van Heeswijk RP, Veldkamp A, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6:201-29.
7. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002; 36:702-6.
8. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2:105-13.
9. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13:213-24.
10. Cameron DW, Angel JB, Ryan J, et al. Durability of ritonavir (RTV) plus saquinavir (SQV) dual protease inhibitor therapy in HIV infections: 5-year follow-up [abstract 550-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
11. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999; 13:2083-9.
12. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13:F95-9.
13. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001; 27:344-9.
14. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000; 44:2672-8.
15. Blaschke T, Flexner C, Sheiner L, Rosenkranz S. Effect of simultaneous or staggered dosing of saquinavir (SQV), ritonavir (RTV), and neffinavir (NFV) on pharmacokinetic (PK) interactions [abstract 76]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retroviruses and Human Health, 2000.
16. Clevenbergh P, Corcostegui M, Gerard D, et al. Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. J Infect 2002; 44:194-5.
17. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002; 36:1598-613.
18. Piscitelli SC, Gallicano KD, Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344:984-96.
19. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 2002; 71:57-67.
20. Burger DM, Prins JM, van der Ende ME, Aarnoutse RE. The influence of nevirapine on the pharmacokinetics of indinavir plus ritonavir 800/100mg Q12h [abstract 7.9]. In: Program and abstracts of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy (Washington, DC). Utrecht, The Netherlands: Virology Education BV, 2002.
21. Solas C, Bosq I, Poizot-Martin I. Therapeutic drug monitoring of lopinavir associated or not with non-nucleoside reverse transcriptase inhibitors: when and why [abstract 7.2]. In: Program and abstracts of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy (Washington, DC). Utrecht, The Netherlands: Virology Education BV, 2002.
22. Boyd M, Duncombe C, Ruxrungtham K, et al. Indinavir TID vs indinavir/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76-week follow-up [abstract 422-W]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
23. Young B, Fischl MA, Wilson HM, et al. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J Acquir Immune Defic Syndr 2002; 31:478-82.
24. Grossman H, Luber AD, Butcher D, et al. Salvage therapy with twice daily indinavir (Crixlvan) 800 mg plus ritonavir (Norvir) 200 mg based regimen in clinical practice (abstract 27). In: Program and abstracts of the 3rd International Workshop on Salvage Therapy for HIV Infection (Chicago). London: International Medical Press, 2000.
25. Hoetelmans RMW, van Heeswijk RP, Meenhorst PL. Plasma concentrations of saquinavir (SQV) determine HIV-1 response over a 48-week period [abstract 42261]. In: Conference record of the 12th World AIDS Conference (Geneva). Geneva: Marathon Multimedia, 1998.
26. Kurowski M, Sternfeld T, Hill A, Moecklinghoff C. Comparative pharmacokinetics and short-term safety of twice daily (BID) fortovase/ritonavir and invirase/ritonavir [abstract 432-W]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
27. O'Brien J. Switch of saquinavir 400 mg/ritonavir 400 mg to saquinavir 1000 mg/ritonavir 100 mg during BID four drug antiretroviral therapy [abstract 2.1]. In: Program and abstracts of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy (Washington, DC). Utrecht, The Netherlands: Virology Education BV, 2002.
28. Gerstoft J, Dragsted UB, Cahn P, et al. Final analysis of a randomized trial to evaluate safety and efficacy of indinavir/ritonavir vs saquinavir/ritonavir in adult HIV-1 infection: the MaxCminl trial [abstract H-172]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
29. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998;42:3218-24.
30. Hsu A, Kempf DJ, Granneman R, Sun E. Exploring theoretical mechanisms for lack of resistance to lopinavir/ritonavlr (LPV/r) in antiretroviral (ARV)-naive subjects [abstract 436-W]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
31. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
32. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-9.
33. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002; 36:1193-203.
34. Qazi NA, Morlese JF, Pozniak AL. Lopinavir/ritonavir (ABT-378/r). Expert Opin Pharmacother 2002; 3:315-27.
35. Murphy RL, Brun S, King M, et al. Lopinavir/ritonavir (Kaletra) in antiretroviral naive HIV+ patients: 4 year follow-up [abstract H-165]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
36. Danner S, Brun S, Sylte J, et al. Kaletra (lopinavir/ritonavir) and efavirenz: 72-week safety and efficacy evaluation and phenotypic/genotypic breakpoints in multiple PI-experienced patients [abstract 1-1925]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
37. Hicks C, Brun S, King M, et al. Kaletra (lopinavir/ritonavir) therapy in single protease inhibitor experienced patients: 144 week follow-up [abstract P220]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Athens: Provoli Publicity SA, 2001:147.
38. Castagna A, Danise A, Hasson H, et al. The normalized inhibitory quotient (NIQ) of lopinavir is predictive of viral load response over 48 weeks in a cohort of highly experienced HIV-1 infected individuals [abstract 128]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
39. Wood R, Trepo C, Livrozet JM, et al. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg BID or APV 1200 mg/RTV 200 mg QD given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART-naive HIV-1 infected adults over 12 weeks [abstract 332]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 2001.
40. Goujard C, Vincent I, Meynard JL, et al. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2003; 47:118-23.
41. Arvieux C, Tattevin P, Souala FM, et al. Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients. HIV Clin Trials 2002; 3:125-32.
42. McCallister S, Sabo J, Galkitz L, Mayers D. An open-label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers [abstract 434-W]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
43. Gerstoft J, Mallolas J, Lundgren J, et al. A randomized trial comparing continued indinavir vs. switching to indinavir plus ritonavir in HIV patients having suppressed viral load with indinavir plus two nucleoside analogue reverse transcriptase inhibitors: the best study [abstract O-8]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Athens: Provoli Publicity SA, 2001:19.
44. Matthews G, Gazzard B, Nelson M. Combination indinavir/ritonavir in clinical practice [abstract WePeB4135]. In: Program and abstracts of the XIII International AIDS Conference (Durban, South Africa). Rome: International AIDS Society, 2000.
45. Deeks S, Brun S, Xu Y, et al. ABT-378/ritonavir (ABT-378/r) suppresses HIV RNA to <400 copies/mL in 84% of PI-experienced patients at 48 weeks [abstract 532]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retroviruses and Human Health, 2000.
46. Castagna A, Dragsted UB, Chave JP, et al. The interim analysis of a phase IV randomized, open-label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg bid) vs saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: the maxCmon1 Trial [abstract G1008e]. in: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
47. Dieleman JP, Salahuddin S, Hsu YS, et al. Indinavir crystallization around the loop of Henle: experimental evidence. J Acquir Immune Defic Syndr 2001; 28:9-13.
48. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13:473-8.
49. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
50. Gulick RM, Mellors JW, Havlir D, et al. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133:35-9.
51. Workman C, Whittaker W, Dyer W, Sullivan JL. Combining ritonavir and indinavir decreases IDV associated nephrolithiasis [abstract 677]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1999.
52. Burger DM, Hugen PW, Aarnoutse RE, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr Hum Retrovirol 2001; 26:218-24.
53. Gatell JM, Lange J, Arnaiz JA. A randomized study comparing continued indinavir (800mg tid) vs switching to indinavir/ritonavir (800/100mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleoside analogues: the BID efficacy and safety trial (BEST) [abstract WeOrB484]. In: Program and abstracts of the XIII International AIDS Conference (Durban, South Africa). Rome: International AIDS Society, 2000.
54. Boyd M, Duncombe C, Ruxrungthan K, et al. A randomised, open label trial of indinavir/ritonavir vs indinavir in combination with AZT/3TC for the treatment of HIV infection in nucleoside experienced patients: results of 112 weeks follow-up [abstract G30e]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
55. Boyd M, Duncombe C, Newell M, et al. Indinavir/ritonavir vs indinavir in combination with AZT/3TC for the treatment of HIV infection in nucleoside experienced patients: a randomized, open label trial [abstract 335]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 2001.
56. Solas C, Petit N, Orticoni M, Durand A, Gastaut JA, Lacarelle B. Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data. Pathol Biol (Paris) 2002;50:565-7.
57. Youle M, Mocroft A, Johnson M. Lipid profiles in patients on ritonavir/indinavir containing salvage regimens [abstract 24]. Antivir Ther 1999; 4(Suppl 2):22.
58. Gerstoff J, Dragsted UB, Cahn P, et al. Final analysis of a randomised trial to evaluate safety and efficacy of indinavir/ritonavir versus saquinavir/ritonavir in adult HIV-1 infection: the MaxCmin1 trial [abstract P29]. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection (Glasgow, UK). London: Lippincott Williams & Wilkins, 2002.
59. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
60. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543-9.
61. Cameron DW, Japour A, Farthing C, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naive patients in year two of follow-up [abstract 388]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1998.
62. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998; 12:1722-4.
63. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002;34:1259-63.
64. Fischl MA, Young B, Watkins M, et al. Direct study: a multicenter, open-label, 24-wk pilot study with a 24-wk extension to evaluate the safety, tolerability and efficacy of indinavir-ritonavir 800/100 bid in combination with d4T plus 3TC in HIV-infected individuals [abstract I-1923]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
65. Katner H, Dejesus E, Paar D, et al. Protocol 107: a multicenter, open-label, 24-week study to evaluate the efficacy and safety of indinavir sulfate 800 mg and ritonavir 200 mg BID plus 2 NRTIs bid in HIV-1 infected individuals who require early treatment intervention [abstract 1-1922]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
66. Aarnoute R, Burger DM, van Oosterhout J. Multiple dose pharmacokinetics and tolerability of once-daily nelfinavir and ritonavir combinations in healthy volunteers [abstract 1.3]. In: Program and abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy (Noordwijk, The Netherlands). Utrecht, The Netherlands: Virology Education BV, 2001.
67. van der Ende ME, de Marie S, Gyssens IC, Hugen PWH, Burger DM. Once daily indinavir/ritonavir in patients unable to adhere to a BID regimen [abstract 71]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Athens: Provoli Publicity SA, 2001:73.
68. Cardiello PG, van Heeswijk RP, Hassink EA, et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002;29:464-70.
69. Burger DM, Hugen PW, van der Ende ME, et al. Once-daily indinavir plus ritonavir: preliminary results of the PIPO study. AIDS 2000; 14:2621-3.
70. Suleiman J, Rhodes RR, Campo R, et al. Preliminary results from indinavir and ritonavir in a once-daily regimen [abstract 336]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 2001.
71. Hugen PW, Burger DM, ter Hofstede HJ, et al. Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr 2000; 25:236-45.
72. Saah AJ, Winchell GA, Nessly ML, Seniuk MA, Rhodes RR, Deutsch PJ. Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother 2001; 45:2710-5.
73. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001; 15:1009-18.
74. + patients: 72 week follow-up [abstract TuPeB4445]. In: 14th International AIDS Conference (Barcelona). Barcelona: Prous Science SA, 2002.
75. Shelton MJ, Cloen D, Berenson C, Esch A, Brewer J, Hewitt R. Pharmacokinetics of once daily saquinavir/ritonavir: effects on unbound methadone and alphal-acid glycoprotein [abstract A-492]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
76. Acosta EP, Saag MS, Montaner JSG. Pharmacokinetics and safety of once daily saquinavir soft gel capsules/ritonavir in HiV-infected antiretroviral naive patients [abstract 3.14]. In: Program and abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy (Noordwijk, The Netherlands). Utrecht, The Netherlands: Virology Education BV, 2001.
77. Back DJ, Khoo SH, Gibbons SE, Merry C. The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol 2001; 51:301-8.
78. van Heeswijk RP, Cohen Stuart JW, Burger DM, Beijnen JH, Borleffs JC, Hoetelmans RM. Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. Br J Clin Pharmacol 2002; 53:211-2.
79. Khoo SH, Hennessy M, Mulcahy F, et al. Differences in intracellular drug accumulation between protease inhibitors [abstract 258]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 2001.
80. Peytavin G, Landman R, Lamotte C. Saquinavir plasma and intracellular concentrations in a once daily dosing combinations Fortovase/low-dose ritonavir in a prospective study (IMEA 015) in HIV-infected patients [abstract 3.16]. In: Program and abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy (Noordwijk, The Netherlands). Utrecht, The Netherlands: Virology Education BV, 2001.
81. Chaillou S, Durant J, Garraffo R, et al. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials 2002; 3:493-501.
82. Cardiello PG, Srasuebkul P, Hassink EA, et al. The efficacy, safety, and immunological changes of qd saquinavir-soft gel capsule 1600 mg/ritonavir 100 mg plus dual nucleosides in patients who had an undetectable viral load after 3 years of treatment [abstract 549-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002.
83. Montaner J, Saag MS, Barylski C, Siemon-Hryzyk P. FOCUS study: saquinavir QD regimen versus efavirenz QD regimen 48 week analysis in HIV infected patients [abstract H-167]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
84. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saqulnavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13:F71-7.
85. O'Brien WA, Atkinson TL, Han X. Combination therapy with Indinavir and Ritonavir in antiretroviral treatment-experienced patients [abstract 2209]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
86. Campo R, Suarez G, Miller N. Efficacy of indinavir (IDV)/ritonavir (RTV)-based regimens (IRBR) among patients with prior protease inhibitor failure [abstract]. Antivir Ther 2000; 5(Suppl 2):27.
87. Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72:7532-41.
88. Mo H, Chernyavskiy T, Lu T. Multiple pathways to resistance to ABT-378 observed in vitro selection [abstract 117]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 1999.